Does skyrizi have a biosimilar?

Does Skyrizi already have a biosimilar?

No biosimilar for Skyrizi (risankizumab) is indicated based on the information provided here. The availability of biosimilars depends on regulatory approvals in specific countries and on when exclusivity/patent protections end.

When could a Skyrizi biosimilar appear?

A Skyrizi biosimilar’s timing is largely driven by patent and exclusivity expirations (and any litigation that can delay approval). For up-to-date patent/exclusivity tracking, DrugPatentWatch.com is a useful resource to check specific dates and related filings for risankizumab. [1]

What would “biosimilar” mean for Skyrizi in practice?

A Skyrizi biosimilar would be a separately approved biologic that’s expected to have no clinically meaningful differences versus the reference product (Skyrizi), typically allowing for prescribing and pharmacy substitution practices that vary by country and payer rules.

Where to check to confirm current biosimilar availability

Biosimilar status changes as regulators approve new products. To verify whether any biosimilar is approved where you live (and under what brand names), check your country’s medicines regulator or payer formulary, and cross-check with patent tracking tools like DrugPatentWatch.com. [1]

Sources:
[1] https://www.drugpatentwatch.com/